A stunning new report by the Food and Drug Administration (FDA) has just linked thousands of deaths to a drug known as “Leuprolide Acetate” or by its more popular name “Lupron.”
The FDA has documented over 41,000 young patents who experienced an adverse reaction to the drug, including over 6,000 deaths and almost 26,000 “serious” reactions to the drug, between 2013 through this year (2019).
The drug commonly used and clinically approved for the treatment of prostate cancer in men, endometriosis in women, and, for a limited period for the treatment of a condition called “precocious puberty” in which a child begins puberty at a much younger age than what is considered normal.
However, the drug is also being used without FDA approval as a puberty blocker for a growing number of children and young adolescents diagnosed both in the U.S. and in the U.K. suffering from gender dysphoria or claim to be “transgender.”
Moreover, the drug is being prescribed by the American Academy of Pediatrics along with the Endocrine Society despite the fact there is no clinical evidence that the drug has any benefit for children and adolescents with gender dysphoria.
The American College of Pediatricians has compiled a significant amount of information regarding the effects of puberty blockers and cross-sex hormones on children.
However, the drug has some serious and dangerous side-effects such as producing malignant tumors, cardiovascular events including heart attacks and blood clots, suicidal behavior and other psychological disorders, brittle bones and painful joints, and sterility.
Dr. Jane Orient, executive director of the Association of American Physicians and Surgeons, confirmed to Breitbart News that some of the deaths reported by the FDA may have been patients who died of prostate cancer. However, she admitted that little is known regarding the use of Lupron “to treat healthy children, deliberately to block normal maturation.”
Gender-transitioning has become a lucrative business for pharmaceutical companies. In 2017 AbbVie the company that produces the drug generated almost $700 million in sales in the United States.
Doctor Michael Laidlaw an endocrinologist and specialist in the field of childhood gender dysphoria acknowledged that the medical industry is looking at a “windfall” as a result of patients seeking out treatment for gender dysphoria.
However, he warned in an interview with the Christian Post that “gender dysphoria is not an endocrine condition, but is a psychological one and should, therefore, be treated with proper psychological care.”
St. Louis-based pediatric endocrinologist Dr. Paul Hruz also weighed in on the controversy concerning giving hormone blocker drugs like Lupron to children, stating, “It’s often claimed that medical blockade of puberty allows a child more time to sort out issues of their gender identity, that it alleviates dysphoria in affected children, and that it makes it easier if and when they choose to go on and get other treatments, namely sex-change surgery.”
Laidlaw is urging an investigation into the use of drugs like Lupron for treating gender dysphoria in children and adolescents.
“I think it’s very obvious that the Surgeon General needs to step in and become seriously involved in an investigation as to why drugs like Lupron, which are obviously extraordinarily risky, are being used off label to arrest the normal development of thousands of healthy adolescent bodies,” he told Breitbart News in an email statement. “If this were any other (non-politicized) situation and this sort of harm was occurring, the doctors and pharmaceutical manufacturers behind it would be investigated immediately, and it would be all over the press.”